People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scorpion Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $1.4B | 2024 |
| Amunix Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $203.9M | $3.9B | 2020 |
| Ikena Oncology, Inc. | — | Biotechnology | Series C | $117.6M | $449.1M | 2025 |
| Third Arc Bio, Inc. | — | Biotechnology | Series C | $72.5M | $636.7M | 2024 |
Otello Stampacchia at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Otello Stampacchia on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 2 | 17 |
| Arjun Goyal | 2 | 5 |
| David Hirsch | 1 | 16 |
| James Topper | 1 | 12 |
| Shelley Chu | 1 | 10 |
| Gary Glick | 1 | 7 |
| David Bonita | 1 | 6 |
| Adam Friedman | 1 | 6 |
| Iain Dukes | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| Owen Hughes | 1 | 4 |
| Jean-Francois D. Formela | 1 | 3 |
| Oleg Nodelman | 1 | 3 |
| Jeffrey Albers | 1 | 3 |
| Volker Schellenberger | 1 | 2 |
| Andrew Fedder | 1 | 2 |
| Trisha Millican | 1 | 2 |
| Richard Heyman | 1 | 2 |
| Brian Piper | 1 | 2 |
| Angie You | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.